We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

This study is currently recruiting participants.
Verified January 2017 by Theodore H. Schwartz, Weill Medical College of Cornell University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01767415
First Posted: January 14, 2013
Last Update Posted: January 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Theodore H. Schwartz, Weill Medical College of Cornell University
  Purpose
The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection.

Condition Intervention Phase
Brain Tumors With Ill-defined Margins Drug: Indigo carmine Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

Resource links provided by NLM:


Further study details as provided by Theodore H. Schwartz, Weill Medical College of Cornell University:

Primary Outcome Measures:
  • Extent of Resection [ Time Frame: 48 hours ]
    Evaluation of the extent of resection of the tumor following the indigo carmine infusion to the tumor.


Secondary Outcome Measures:
  • Absence of complications after injection [ Time Frame: 30 days ]

Estimated Enrollment: 30
Study Start Date: March 2012
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Indigo Carmine
Intraoperative stereotactic injection of Indigo Carmine
Drug: Indigo carmine
During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
Other Name: Indigotindisulfonate sodium

Detailed Description:
Low grade gliomas are brain tumors with usually poorly defined borders between tumor and normal brain. This characteristic of low grade gliomas makes the gross total resection of the tumor extremely difficult. Nevertheless, several studies have demonstrated that the risk of recurrence and progression into a more malignant tumor can be decreased with a more aggressive surgical resection. An aggressive attempt to achieve a gross total resection may result in the resection of normal brain and therefore neurological injury. For this reason, the more common error is to subtotally resect the tumor leaving significant volumes of tumor behind. Many techniques have been introduced to safely increase the extent of resection, since the extent of resection is associated with a higher survival rate. Each one of these techniques has several shortcomings. The current study will assess whether the intraoperative stereotactic injection of the indigo carmine at the tumor margins helps to safely increase of extent of tumor resection. In the first step of the study the safety and the correlation between resection of stained tissue/extend of tumor resection will be assessed. If the results are satisfactory, then the second step will ensue. In the second step we will assess the utility of indigo carmine as an additional adjunct to guide tumor resection.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with gliomas or other tumors that may have ill defined margins during the operative resection.

Exclusion Criteria:

  • Subjects with a contraindication for brain MRI scan. Subjects who are pregnant, younger than 18 years old or have a contraindication for indigo carmine are excluded as well
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01767415


Contacts
Contact: Theodore Schwartz, MD 212-746-5620 schwarh@med.cornell.edu
Contact: Samantha Bui 212-746-1788 xeb2001@med.cornell.edu

Locations
United States, New York
Weill Cornell Medical College Department of Neurological Surgery Recruiting
New York, New York, United States, 10065
Contact: Theodore Schwartz, MD    212-746-5620    schwarh@med.cornell.edu   
Contact: Samantha Bui    212-746-1788    xeb2001@med.cornell.edu   
Principal Investigator: Theodore Schwartz, MD         
Sub-Investigator: Jeffrey Greenfield, MD, PhD         
Sub-Investigator: Mark Souweidane, MD         
Sub-Investigator: Philip Stieg, MD, PhD         
Sub-Investigator: Prajwal Rajappa, MD         
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Principal Investigator: Theodore Schwartz, MD Weill Medical College of Cornell University
  More Information

Responsible Party: Theodore H. Schwartz, Professor of Neurological Surgery, Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT01767415     History of Changes
Other Study ID Numbers: 1106011772
First Submitted: January 10, 2013
First Posted: January 14, 2013
Last Update Posted: January 13, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Theodore H. Schwartz, Weill Medical College of Cornell University:
brain tumor
resection
indigo carmine dye

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases